MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

14.72 -0.74

Overview

Share price change

24h

Current

Min

14.66

Max

14.74

Key metrics

By Trading Economics

Income

111M

144M

Sales

9.2M

260M

P/E

Sector Avg

10.574

57.333

EPS

0.86

Profit margin

55.37

Employees

653

EBITDA

-19M

12M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+73.12% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

-706M

2.4B

Previous open

15.46

Previous close

14.72

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Apr 2025, 17:01 UTC

Earnings
Major Market Movers

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25 Apr 2025, 16:10 UTC

Earnings
Major Market Movers

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26 Apr 2025, 18:14 UTC

Earnings

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

26 Apr 2025, 15:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26 Apr 2025, 08:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

25 Apr 2025, 21:24 UTC

Top News

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25 Apr 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

25 Apr 2025, 20:45 UTC

Top News

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25 Apr 2025, 20:39 UTC

Earnings

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25 Apr 2025, 20:37 UTC

Top News

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25 Apr 2025, 20:19 UTC

Top News

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25 Apr 2025, 20:15 UTC

Earnings

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25 Apr 2025, 19:23 UTC

Market Talk

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25 Apr 2025, 19:18 UTC

Market Talk

Oil Futures End Choppy Week With Losses -- Market Talk

25 Apr 2025, 18:47 UTC

Market Talk

Gold Extends Pullback to Close Week -- Market Talk

25 Apr 2025, 18:39 UTC

Top News

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25 Apr 2025, 18:34 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25 Apr 2025, 18:32 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

25 Apr 2025, 18:32 UTC

Market Talk
Earnings

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25 Apr 2025, 18:08 UTC

Earnings

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25 Apr 2025, 17:55 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25 Apr 2025, 17:40 UTC

Top News

Consumers Continue to Sour on the Economy -- 4th Update

25 Apr 2025, 17:38 UTC

Earnings

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25 Apr 2025, 17:07 UTC

Market Talk

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25 Apr 2025, 16:54 UTC

Market Talk
Earnings

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25 Apr 2025, 16:46 UTC

Earnings

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25 Apr 2025, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

25 Apr 2025, 16:12 UTC

Top News

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25 Apr 2025, 16:03 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 Apr 2025, 15:52 UTC

Market Talk

Grains Mixed on Low Volume Trade -- Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

73.12% upside

12 Months Forecast

Average 25.5 USD  73.12%

High 37 USD

Low 18 USD

Based on 16 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

10

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

14.58 / 14.86Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.